Given Warren Buffet's proclivity for only owning stock of companies that he understands inside and out, these 10 top health care picks with big, dependable dividends make sense now for growth and…
Two Dow stocks and the country's largest independent oil producer are reporting quarterly results before markets open Thursday.
Here are the S&P 500 stocks moving up or down the most in Wednesday's premarket trading session.
Here is a look at the stocks currently in the running to be Dogs of the Dow for 2022.
Friday’s top analyst upgrades and downgrades included Bank of New York Mellon, Canoo, Cigna, Fiserv, Invesco, Merck, ONEOK, Progressive, Robinhood Markets, Ross Stores and Wayfair.
Monday’s top analyst upgrades and downgrades included Apple, Coca-Cola, CommScope, Coupa Software, GoPro, HubSpot, Merck, NetApp, Pfizer, Shopify, Spirit Airlines and Warner Music.
Tuesday’s top analyst upgrades and downgrades included Bloomin' Brands, Boston Beer, Bumble, Goldman Sachs, Juniper Networks, Merck, Moderna, Petco Health, Southern Company, Spirit Airlines and Wells Fargo.
Merck, Stryker and these other companies are expected to lift the dividends they pay to shareholders, and their stocks are rated Buy across Wall Street, making them excellent total return candidates.
Monday’s top analyst upgrades and downgrades included Affirm, BlackRock, Deere, Dick's Sporting Goods, Dollar Tree, Intercontinental Exchange, Mastercard, Merck, Nordstrom, Petrobras and Pure Storage.
McCormick, Merck and these other top companies are expected to lift the dividends they pay to shareholders, and their stocks are rated Buy across Wall Street, making them excellent total return candidates.
Merck, Nike and these other top companies are expected to lift the dividends they pay to shareholders, and their stocks are rated Buy across Wall Street, making them excellent total return candidates.
Monday afternoon's analyst upgrades and downgrades included Bristol-Myers Squibb, Intel, Merck, Newell Brands, Snap, Spotify Technology and Tilray.
In this massively overbought market, health care stocks could benefit from a shift toward more defensive sectors. These five offer strong balance sheets, attractive dividend yields and improved cost structures, and they…
While the quantitative easing soon will begin to dwindle, it is highly unlikely the Federal Reserve actually will raise interest rates until 2023, so buying blue-chip stocks with solid total return potential…
